Multiple Dose Pharmacokinetics of Intranasal Ketamine

Javelin Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: intranasal ketamine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00519987

KET-PK-002

Details and patient eligibility

About

This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

Full description

To examine safety and characterize the repeat dosing plasma profile, effect on absorption, and accumulation following repeated administration of 30 mg doses of PMI-150 (intranasal ketamine) to healthy adult volunteers.

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adults

Exclusion criteria

• under 18 years

Trial design

18 participants in 1 patient group

Treatment A

Experimental group

Description:

intranasal ketamine

Treatment:

Drug: intranasal ketamine